entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 22:41:38 - browse：97376

A product image of the Cue reader COVID-19 home use test — Businesswire via AP

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company last week that said Cue was not following the conditions stipulated in the emergency use authorizations for its tests.

The FDA letters said the tests could give false results. Specifically, the agency said that the company had changed how the electrochemical signals within the test device were generated, received, and interpreted — changes the FDA has not authorized. These changes decreased the stability of the tests and might lead to false results, the agency said.

The FDA warnings come near what might be the end of a spectacularly bumpy ride for the company. When Cue went public in 2021, it was valued at nearly $3 billion. It supplied tests for the NBA’s 2020 “bubble,” leading a Trump administration official to proclaim that if the test was “good enough for LeBron,” the administration would bring it to the American people — and it did, in a $481 million deal.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Scientists grapple with ethics of stem cell research

WSS

H5N1 bird flu outbreak: Second human case reported, in Michigan

Hormonal contraceptives don’t actually treat endometriosis

Delta passengers in Vegas fall sick while waiting on flight in triple

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Digital health: a case of mistaken identity

UnitedHealth argues against case alleging wrongful AI care denials

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

BioMarin wins approval for gene therapy to treat hemophilia A

US jobless claims fall again as labor market continues to flash strength

Heart attack and stroke risk calculators need revising

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

State Dept. review finds Biden bears some blame for Afghanistan failures

Bird flu surveillance in wastewater gets boost from consortium

Medical records are filled with copy

Scientists grapple with ethics of stem cell research

Sports medicine is finally prioritizing gender equality

'CMA Fest' 2023: How to watch, who is performing and more

hotspot

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Telehealth startups are trying to fill the menopause care vacuum

Fentanyl is making it harder to start addiction treatment

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

When a patient nears the end, a feared therapy can comfort

In rare move, senator releases unverified FBI source report alleging Biden bribe

Wikipedia

explore

focus

focus